Drug Trial Radar · NCT05452772
5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder
Last checked: Nov 20, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
66
Planned (sponsor's estimate)
Start
Nov 1, 2023
Primary completion
Dec 2026
Study completion May 2027
Sponsor
- Lead sponsor
- Johns Hopkins UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Alabama at Birmingham; New York University; National Institute on Drug Abuse (NIDA)
- First posted
- Jul 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 21 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a multi-site, double-blind, randomized clinical trial of the 5-HT2A receptor agonist psilocybin for smoking cessation. Four sites with experience in conducting psilocybin research will be involved in this trial: Johns Hopkins University (JHU), the University of Alabama at Birmingham (UAB), and New York University (NYU). The proposed study will treat 66 participants (22 at each site), randomized to receive either: 1) oral psilocybin (30 mg in session 1 and either 30 mg or 40 mg in session 2); or 2) oral niacin (150 mg in session 1 and either 150 mg or 200 mg in session 2), with sessions 1 week apart.
Conditions
- Tobacco Use Disorder
Interventions
PsilocybinDrug
Participants will received two psilocybin sessions, 1 week apart
NiacinDrug
Participants will received two niacin sessions, 1 week apart
Primary outcomes
What the sponsor says the trial is designed to measure.
- Potential Efficacy (Smoking Cessation)Time frame: 12 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
Johns Hopkins University School of Medicine
Baltimore, Maryland · Active not recruiting
New York University
New York, New York · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.